StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences capital expenditures (Form 8-K Selected Cash Flow Information, $M) ($M)

Form 8-K Selected Cash Flow Information

QuarterlyAnnual
Latest, Q2 2026
140
Period ended Jun 30, 2026
Change on a year earlier
+30.8%
107 in Q2 2025
History
26 quarters
Since Q1 2020
Sources
22
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCapital expenditures (Form 8-K Selected Cash Flow Information, $M) ($M)Year on yearSource
Q2 2026Jun 30, 2026140+30.8%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026117+12.5%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 2025205+39.5%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 2025147+5.0%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025107-17.7%Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025104-1.0%Form 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2024Dec 31, 2024147-31.3%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2024Sep 30, 2024140+14.8%Form 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 2024130-6.5%Form 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2024Mar 31, 2024105-3.7%Form 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 2023214+18.2%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2023Sep 30, 2023122-22.3%Form 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2023Jun 30, 2023139-2.8%Form 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2023Mar 31, 2023109-55.9%Form 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 2022181+16.0%Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2022Sep 30, 2022157+12.9%Form 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences Capital expenditures (Form 8-K Selected Cash Flow Information, $M) ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rel_capex_row

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.